Atherosclerosis-targeted liposome nanocarrier delivery system and preparation method therefor
US-2024424132-A1 · Dec 26, 2024 · US
Pharmaceutical composition containing clioquinol for treating autism spectrum disorders
US2016120858A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016120858-A1 |
| Application number | US-201514932812-A |
| Country | US |
| Kind code | A1 |
| Filing date | Nov 4, 2015 |
| Priority date | Nov 5, 2014 |
| Publication date | May 5, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a pharmaceutical composition for treating autism spectrum disorders, which includes clioquinol or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a food composition for treating autism spectrum disorders, which includes clioquinol or pharmaceutically acceptable salt thereof.
First claim
Opening claim text (preview).
What is claimed is: 1 . A pharmaceutical composition for treating autism spectrum disorders, which comprises clioquinol or pharmaceutically acceptable salt thereof. 2 . The pharmaceutical composition of claim 1 , wherein the clioquinol enhances postsynaptic NMDA receptor function. 3 . The pharmaceutical composition of claim 1 , wherein the clioquinol enhances NMDA receptor function through Zn ionophore activation. 4 . The pharmaceutical composition of claim 1 , wherein the clioquinol enhances NMDA receptor function through Src family tyrosine kinase. 5 . The pharmaceutical composition of claim 1 , wherein the clioquinol promotes Zn mobilization in synapses. 6 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition improves social interaction deficiency. 7 . The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is administered through injection. 8 . A food composition for treating autism spectrum disorders, which comprises clioquinol or pharmaceutically acceptable salt thereof. 9 . The food composition of claim 8 , wherein the clioquinol enhances postsynaptic NMDA receptor function. 10 . The food composition of claim 8 , wherein the food composition improves social interaction deficiency.
Assignees
Inventors
Classifications
Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title
- A61K31/47Primary
Quinolines; Isoquinolines · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Drugs for disorders of the nervous system · CPC title
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016120858A1 cover?
- The present invention relates to a pharmaceutical composition for treating autism spectrum disorders, which includes clioquinol or pharmaceutically acceptable salt thereof. In addition, the present invention relates to a food composition for treating autism spectrum disorders, which includes clioquinol or pharmaceutically acceptable salt thereof.
- Who is the assignee on this patent?
- Academia Sinica, Inst Basic Science, Korea Advanced Inst Sci & Tech, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/47. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu May 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).